Zdorovʹe Rebenka (Mar 2017)
Correction of metabolic disorders in acetonemic syndrome in children with functional disorders of the biliary tract
Abstract
Background. Acetonemic syndrome (AS) is one of the common pathological conditions in children. The most important part of the therapy for AS is to prevent the metabolic disorders in acetonemic crisis in children. Purpose — to study the effectiveness of Gepargin® in the treatment of children with acetonemic syndrome and to assess the dynamics of clinical and laboratory indicators. Materials and methods. We have analyzed the results of the medical examination and treatment of 40 children aged 3–10 years with AS and functional disorders of the biliary tract. The survey was conducted according to the generally accepted scheme [6]. To determine the level of ketone bodies in urine, a standard laboratory method for determining acetoacetate in urine was used. The degree of ketonuria was recorded from “+” to “++++”. All patients received basic therapy, according to the unified treatment protocols, and Gepargin®. The contents of the vial were diluted in half a glass (100 ml) of drinking water and taken in 3–4 doses during the day. Duration of treatment was 5 days (before arresting the acetonemic crisis). The effectiveness of the therapy was assessed by the dynamics of complaints, state of health, clinical symptoms and laboratory data. Results. During the observation, we noted positive dynamics in the course of acetonemic syndrome. On admission to the hospital, 17 (42.5 %) children had ketonuria “++++”, 15 children (37.5 %) — “+++”, 3 (7.5 %) — “++”, and 5 (12.5 %) — “+”. In the process of Gepargin® treatment, we noted a significant decrease (by 76.5 %) in the number of children with ketonuria “++++”, and by 87 % — with ketonuria “+++”. From the 3rd day of Gepargin® treatment, none of the children had ketonuria. Conclusions. The effectiveness of Gepargin® in the comprehensive therapy of AS in children consisted in the relief of clinical symptoms. This use of this drug is pathogenetically substantiated for the correction of metabolic disorders in ketoacidosis. Gepargin® is well tolerated, it is convenient for the use in children from an early age. The results of this observation suggest using Gepargin® in basic therapy of acetonemic disorders in childhood.
Keywords
